Articles tagged with Tumor Growth
Researchers at UCSF have discovered a new type of stem cell in the young brain that can form cells found in tumors, shedding light on how adult brain cells grow and develop into deadly brain cancers. The study provides a comprehensive roadmap for understanding healthy brain development, which could lead to better treatments for conditi...
The study found that high levels of aspartate in the lungs are associated with aggressive lung metastases, triggered by an alternative translation program driven by aspartate signaling. This discovery suggests a common feature of cancer cells growing in the lung and provides a potential target for new therapeutic interventions.
Researchers discovered that aggressive breast cancer prompts nearby immune cells to build 'molecular bridges' between themselves, suppressing the immune response. An antibody treatment that blocks these bridges was shown to restore the immune system's ability to attack with force, inhibiting tumor growth in a mouse model.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
A new Northwestern Medicine study reveals how metformin lowers glucose levels by targeting mitochondrial complex I in cells. The drug also improves COVID outcomes and reduces inflammation, suggesting that mitochondrial complex I inhibition may be a unifying mechanism behind its diverse effects.
Craniopharyngiomas, a type of brain tumor, can hijack hypothalamic neurons to enhance growth. Researchers identified a promising treatment option: amlodipine besylate, a calcium channel blocker commonly used for hypertension. The medication disrupts chemical synaptic transmission between neurons and tumor cells.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.
Researchers at the University of Alabama at Birmingham have identified HIF1α as a key regulator that induces cancer-killing capacity in T cells under hypoxic conditions. In this study, they found that HIF1α-glycolysis is indispensable for IFN-γ induction in hypoxic T cells.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A study by Tulane University researchers found that tumors in female fruit flies grew 2.5 times larger than those in male fruit flies due to sex-based differences in immune response. The stronger innate immune response in females accelerated tumor growth.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
Researchers at Sanford Burnham Prebys found that pancreatic cancer cells rely on a specific nutrient, glutamine, to fuel their unchecked growth. The study identified two enzymes, aPKC zeta and iota, that play a regulatory role in the process of macropinocytosis, allowing cancer cells to scavenge alternative resources.
A study published in Nature reveals that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer. The liver converts fructose into usable nutrients for cancer cells, a finding that could lead to new treatment avenues.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
Researchers activate glycoprotein 130 and its associated signaling pathway to slow down tumor growth in prostate cancer, stimulating immune system to fight tumour cells. Studies of tissue samples from prostate cancer patients show positive correlation with better survival rates.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Researchers found that non-invasive stereotactic radiosurgery significantly improves tumor control and reduces symptoms such as tinnitus, cranial nerve deterioration, and vestibular dysfunction. Early treatment can prevent tumors from growing over time and spare patients from irreversible problems.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
A study by Texas A&M University has revealed high levels of lead, barium, and chromium in soil samples from the Greater Fifth Ward neighborhood. The findings highlight the need for environmental protection programs to address health risks associated with heavy metal exposure.
A new University of Cincinnati Cancer Center study reveals how copper helps clear cell renal cell carcinoma cells grow and advance. Copper accumulation is associated with worse outcomes for patients with ccRCC, and it boosts energy and growth in cancer cells.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
The TTUHSC team will conduct a needs assessment and create an action plan to strengthen clinical and community-based research, guided by strategic translational research themes. The goal is to address health disparities in the region through community-based participatory research.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
A study published in the Chinese Medical Journal projects a significant rise in global thyroid cancer burden, with 821,214 new cases and 47,507 related deaths reported worldwide in 2022. The incidence is expected to increase by 44.1% from 2019 to 2030, with women experiencing higher rates than men.
Researchers at Umea University have discovered how embryonic stem cells transition into specialized cells, highlighting the importance of LSD1 protein in cancer development. The study suggests that targeting only LSD1's enzymatic activity may not be enough for cancer treatments to be effective.
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
Researchers discovered TERT gene activation as a key factor in determining the clinical course of pulmonary carcinoid tumours, with aggressive growth linked to telomerase activation. The study aims to improve treatment planning and targeted therapeutic strategies for cancer types.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
A new study published in Frontiers in Immunology reveals that certain food proteins like milk and meat can help keep gut tumors from growing by triggering the intestinal immune system. This discovery has potential clinical implications for patients with gastrointestinal conditions.
The University of Oklahoma Health Sciences has received a $5.3 million National Institutes of Health grant to support advanced cancer research in Oklahoma. The grant will help early-career researchers establish independently funded laboratories and build technology infrastructure specific to cancer investigations.
Researchers at UCSF used cryogenic electron microscopy to study the protein TGF-Beta, which plays a crucial role in development and cancer. They found that TGF-Beta can signal even when bound to a 'straitjacket' within the cell membrane, challenging decades-old dogma on its function.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
A new study found that cystic fibrosis patients with more severe disease characteristics exhibit shorter leukocyte telomere length and greater LTL attrition. This association may accelerate aging and increase susceptibility to age-related diseases, emphasizing the importance of early CF diagnosis and timely therapeutic intervention.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
Researchers propose a new approach to understanding cancer evolution, acknowledging the importance of environmental influences and epigenetic changes. By refining the clonal evolution model, they aim to develop more effective cancer therapies that consider the full complexity of cancer cell evolution.
A glitch in protein synthesis, known as stop codon readthrough, may affect tumour growth and cancer cell proliferation. The study found that preventing this process can lead to increased degradation of target proteins and a delayed cell cycle, resulting in slower tumour growth.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
A common skin fungus, Malassezia globosa, may invade deep tissues and cause tumor growth in breast cancer, according to a new study published in mBio. The researchers found that M. globosa colonizes in breast fat pads leading to tumor growth, suggesting a potential link between fungal colonization and cancer progression.
A new study reveals that the menstrual cycle plays a role in spreading mutant cells within mammary tissue, leading to large fields prone to tumor formation. Researchers observed that the growth and removal of extra milk ducts during the menstrual cycle can contribute to this process.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Researchers create superhydrophobic array device (SHArD) mimicking the lotus leaf surface structure, enabling high-throughput generation of three-dimensional nanoscale tumor models. This platform helps study metastasis and primary tumors, shedding light on cancer progression.
Researchers found that targeting and silencing ERBB2 gene expression significantly increases chances of stopping tumor growth in mice with a PTEN mutation. This breakthrough may lead to alternative treatment options for endometrial cancer patients, reducing the risk of fertility issues associated with standard treatments.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.